A COMBINED CHEMOENDOCRINE TREATMENT WITH TEGAFUR, ADRIAMYCIN, METHOTREXATE AND TAMOXIFEN FOR ADVANCED RENAL-CELL CARCINOMA

Eight patients with advanced renal cell carcinoma were given a new che mo-endocrine treatment with tegafur, adriamycin, methotrexate and tamo xifen. Estrogen receptor was detected in five cases from renal or meta static tumors. The patients were medicated with 800-1, 200mg of tegafu r and 20 mg of tamoxifen daily po and 20mg of adrimycin and 10 mg of m ethotrexate iv intermittently at two week intervals. Two patients were regarded as CR, two as PR, one as NC and three as PD. Two out of thre e with estrogen receptor and one out of two without estrogen receptor responded favorably to this treatment. Side effects observed during th e treatment were Grade II nausea/vomiting in six, Grade II leukopenia in three, Grade I thrombocytopenia in two, and Grade I hepatoxicity in three patients. The patients were found to be enjoying a good quality of life during the treatment because of lowered toxicity. This treatm ent can be regarded as a good treatment modality for advanced renal ce ll carcinoma.